Title: Evaluation of short- and long-term response to treatment in GIMEMA protocol for Acute Myeloid Leukaemia

Authors: I. Ardoino, F. Ambrogi, S. Iacobelli, P. Boracchi, G. Manikis, M.G. Kounelakis, M. Zervakis, P.J.G. Lisboa, P. Fazi, M. Vignetti, E.M. Biganzoli, A. Starita

Addresses: Institute of Medical Statistics and Biometry ''Giulio A. Maccacaro'', Campus Cascina Rosa – National Cancer Institute, Via Venezian 1, 20133 Milan, Italy. ' Institute of Medical Statistics and Biometry ''Giulio A. Maccacaro'', Campus Cascina Rosa – University of Milan, Via Venezian 1, 20133 Milan, Italy. ' Dipartimento SpeS – Universita degli Studi del Molise, C/da Tappino, 86100 Campobasso, Italy. ' Institute of Medical Statistics and Biometry ''Giulio A. Maccacaro'', Campus Cascina Rosa – University of Milan, Via Venezian 1, 20133 Milan, Italy. ' Department of Electronic and Computer Engineering, Technical University of Crete, Chania 73100, Crete, Greece. ' Department of Electronic and Computer Engineering, Technical University of Crete, Chania 73100, Crete, Greece. ' Department of Electronic and Computer Engineering, Technical University of Crete, Chania 73100, Crete, Greece. ' School of Computing and Mathematical Sciences, Liverpool John Moores University, Byrom Street Liverpool L3 3AF, UK. ' GIMEMA Foundation Data Center, Via Benevento 6, 00161 Rome, Italy. ' GIMEMA Foundation Data Center, Via Benevento 6, 00161 Rome, Italy. ' Institute of Medical Statistics and Biometry ''Giulio A. Maccacaro'', Campus Cascina Rosa – National Cancer Institute, Via Venezian 1, 20133 Milan, Italy ' Institute of Medical Statistics and Biometry ''Giulio A. Maccacaro'', Campus Cascina Rosa – University of Milan, Via Venezian 1, 20133 Milan, Italy. ' Dipartimento di informatica – Universita degli Studi di Pisa, Largo B. Pontecorvo 3, 56127 Pisa, Italy

Abstract: Acute Myeloid Leukaemia (AML) is a haematologic malignancy. Despite of improvements in prognosis it is still a severe disease and only a minority of patients are cured. Recently, insights into specific cytogenetics and biological aberration involved in the leukaemogenesis process are the target of research. LAM-99P GIMEMA Protocol identifies treatment guidelines for AML in adults. A methodological approach is proposed, compounding different modelling techniques, to assess the prognostic relevance of clinical as well as biological markers with regard to clinical endpoint, such as the achievement of Complete Remission in the short-term and long-term survival taking into account competing risks.

Keywords: AML; acute myeloid leukaemia; survival analysis; competing risks; multinomial logistic regression; support vector machines; SVM; long-term response; short-term response; leukaemia treatment; LAM-99P GIMEMA Protocol; modelling; clinical markers; biological markers.

DOI: 10.1504/IJBET.2010.032699

International Journal of Biomedical Engineering and Technology, 2010 Vol.3 No.3/4, pp.329 - 348

Published online: 13 Apr 2010 *

Full-text access for editors Full-text access for subscribers Purchase this article Comment on this article